Kanjinti and Mvasi Make ‘Solid Start’ In US
Amgen’s Global Biosimilars Annualizing At Around $700m
Executive Summary
Launching its Kanjinti and Mvasi trastuzumab and bevacizumab biosimilars ‘at risk’ in July generated third-quarter sales of $81m for Amgen, contributing nearly half of global biosimilar turnover of $173m.
You may also be interested in...
Pfizer Launches US Bevacizumab At A 23% Discount
Pfizer is getting ready to ship its Zirabev biosimilar rival to Avastin in the US, at a price that represents a 23% discount to the brand and is also lower than the price for Amgen’s Mvasi biosimilar.
Amgen And Allergan File For US Rituximab
Amgen’s FDA submission for a biosimilar of Roche’s Rituxan rituximab brand comes shortly after Teva launched the first direct rival to the oncology drug in the US.
Amgen Gets US Infliximab Nod
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.